Vasopressin is given by continuous infusion to people in shock, in intensive care or an operating theatre, alongside other blood-pressure drugs. That setting shapes everything in its side-effect record: the people receiving it are already critically ill, and the US label lists what can go wrong without saying how often.
This page reports what the label states, what two large trials counted, and what FDA's adverse-event database holds. It is a record of sources and is not medical advice.
What the label covers
Vasostrict (vasopressin injection, Par Health USA) is the brand-name US product. Its label on DailyMed carries an effective date of 21 April 2026 and one indication: to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The label records initial US approval in 2014.
On 11 November 2026 DailyMed listed 27 vasopressin label records, four of them under the Vasostrict name and the rest generic or premixed versions. This page reads the Vasostrict label only.
What vasopressin is, as a molecule, is covered in Peptide Lexicon's vasopressin entry. How it differs from its synthetic relative is on our desmopressin vs vasopressin comparison.
The adverse reactions the label lists
The label's summary line names the most common adverse reactions as decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital).
Its full list, by body system:
| Body system | Reactions listed | Frequency given |
|---|---|---|
| Bleeding and lymphatic | Hemorrhagic shock, decreased platelets, intractable bleeding | None |
| Heart | Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia | None |
| Gut | Mesenteric ischemia | None |
| Liver and bile | Increased bilirubin levels | None |
| Kidney | Acute renal insufficiency | None |
| Blood vessels | Distal limb ischemia | None |
| Metabolic | Hyponatremia | None |
| Skin | Ischemic lesions | None |
| Postmarketing | Reversible diabetes insipidus | None |
Source for every row: Vasostrict prescribing information, section 6, label effective 21 April 2026 (kind of source: approved label).
The empty right-hand column is the label's own position. It states that the reactions "were identified in the literature" and that, because they are reported voluntarily from a population of uncertain size, "it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure."
Most of the list follows from what the drug does. The label's pharmacology section says vasopressin narrows blood vessels "in most vascular beds including the splanchnic, renal and cutaneous circulation". Narrowing that raises blood pressure can also reduce blood flow to the gut, the skin and the fingers and toes.
The two warnings
The label has no boxed warning. It has two numbered warnings.
Worsening cardiac function. The label's text is one sentence: "A decrease in cardiac index may be observed with the use of vasopressin." Elsewhere it says vasopressin "tends to decrease heart rate and cardiac output."
Reversible diabetes insipidus. After the infusion stops, some patients pass large volumes of dilute urine and their blood sodium rises. The label directs monitoring of serum electrolytes, fluid status and urine output after discontinuation, and says some patients "may require readministration of vasopressin or administration of desmopressin". The sodium record of that second drug is set out on our desmopressin side-effects page.
Overdose, as the label describes it
The label says overdosage "can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia", and less commonly as ventricular tachyarrhythmias including torsade de pointes, rhabdomyolysis and non-specific gut symptoms. It adds that "direct effects will resolve within minutes of withdrawal of treatment". The label puts the drug's apparent half-life at 10 minutes or less at the infusion rates used in shock.
What the trials counted instead
Because the label gives no rates, the nearest thing to a frequency comes from randomised trials that compared vasopressin with norepinephrine, the standard first drug in septic shock. Both figures below are taken from the trials' published abstracts.
| Trial | Patients | Serious adverse events, vasopressin | Serious adverse events, norepinephrine | Result |
|---|---|---|---|---|
| VASST, NEJM 2008 (PMID 18305265) | 778 adults with septic shock | 10.3% | 10.5% | P=1.00 |
| VANISH, JAMA 2016 (PMID 27483065) | 409 adults with septic shock | 22 of 205 (10.7%) | 17 of 204 (8.3%) | Difference 2.5 points, 95% CI -3.3 to 8.2 |
Kind of source: trial publication. Neither difference was statistically significant.
Three limits on reading that table:
- Both trials compared vasopressin with another blood-pressure drug, not with placebo. A similar serious-event rate means the two drugs looked alike on that count in those patients. It does not mean either rate was caused by the drug.
- VASST used 0.01 to 0.03 units per minute. The label's range for septic shock runs to 0.07 units per minute, so the trial does not describe the upper part of the labelled range.
- Neither abstract breaks serious events down by type. This page did not open the full papers' tables, so it gives no per-event counts such as digital ischaemia.
One finding runs against the label's list. Atrial fibrillation is on the label as an adverse reaction. A 2018 meta-analysis of randomised trials in cardiac surgery (625 patients, PMID 29748077) reported fewer cases of new-onset atrial fibrillation with vasopressin than with standard therapy (odds ratio 0.42, 95% CI 0.21 to 0.82). The authors also wrote that every included trial had a high risk of bias and that the funnel plot suggested publication bias. The two statements are not in conflict so much as built differently: the label collects reports of events during use, and the meta-analysis compares rates between groups.
What 4,443 adverse-event reports show
On 11 November 2026, openFDA returned 4,443 adverse-event reports in which vasopressin is named, with the dataset last updated 28 October 2026. The most frequent coded terms:
| Coded term | Reports |
|---|---|
| Drug ineffective | 1,360 |
| Off label use | 560 |
| Hypotension | 517 |
| Cardiogenic shock | 428 |
| Multiple organ dysfunction syndrome | 424 |
| Sepsis | 415 |
| Condition aggravated | 405 |
| Toxicity to various agents | 343 |
| Acute kidney injury | 342 |
Query: patient.drug.openfda.generic_name:"vasopressin", counted by reaction term (kind of source: regulator's spontaneous-report database).
The list reads as a description of the patients more than of the drug. Hypotension, sepsis, cardiogenic shock and organ failure are the conditions vasopressin is given for. The most frequent term of all records that blood pressure did not respond.
The database's own notice, returned with every query, reads: "Do not rely on openFDA to make decisions regarding medical care," and says results should be assumed unvalidated. A spontaneous report records that an event happened in someone who received a drug; it does not show the drug caused it, and report counts are not rates. This count does not separate reports where vasopressin was the suspected drug from those where it was one of many drugs given.
Interactions the label names
The label lists five groups of drugs that change vasopressin's effect: catecholamines (additive effect on blood pressure), indomethacin (prolongs the effect), ganglionic blocking agents (increase it), drugs suspected of causing the syndrome of inappropriate antidiuretic hormone, such as certain antidepressants (may increase the pressor and antidiuretic effects), and drugs suspected of causing diabetes insipidus, such as lithium (may decrease them).
Pregnancy, children and older adults
- Pregnancy. The label says there are no available data in pregnant women and that the drug "may produce tonic uterine contractions that could threaten the continuation of pregnancy." It reports that clearance rises about 4-fold by the third trimester.
- Breastfeeding. No data on presence in milk or effects on the infant.
- Children. Safety and effectiveness in children with vasodilatory shock "have not been established."
- Older adults. The label says trials did not include enough people aged 65 and over to tell whether they respond differently, and that other clinical experience has not identified differences.
Vasopressin outside a hospital
The Vasostrict label has one use, the treatment of shock, and describes intravenous infusion only. It is one of the approved drugs on our list of FDA-approved peptides. Vials sold online under the same name as research material carry no label and no approved quality record; what a seller's certificate can and cannot show is covered in our guide to reading a certificate of analysis. Nothing in the label's record describes such products.
What is not established
- How often any listed reaction occurs. The label gives no percentage for any adverse reaction.
- Whether listed reactions are caused by the drug or by shock itself. The label says a causal relationship cannot be established from the reports it draws on.
- Per-event rates in the trials. This page read the VASST and VANISH abstracts, which report serious adverse events in total only.
- Safety in children and in pregnancy. The label states the absence of data for both.
- Differences between versions. One Vasostrict label was read; the other 26 vasopressin label records listed were not compared.
Who makes the decisions
Vasopressin is started, adjusted and stopped by intensive-care and anaesthesia teams with continuous monitoring. Questions about its use in a particular person belong with those clinicians. This page describes the published record and does not replace the label.
Sources and dates
- Vasostrict (vasopressin injection), Par Health USA, US prescribing information, DailyMed listing, label effective 21 April 2026, read 11 November 2026. Sections 1, 4, 5, 6, 7, 8, 10 and 12 are the basis for every label statement above.
- DailyMed label search for "vasopressin": 27 records, read 11 November 2026.
- Russell JA et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–87. PMID 18305265. Abstract read.
- Gordon AC et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509–18. PMID 27483065. Abstract read.
- Dünser MW et al. Vasopressin in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2018;32(5):2225–32. PMID 29748077. Abstract read.
- openFDA drug adverse-event endpoint, query as printed above, read 11 November 2026; dataset last updated 28 October 2026.
